☰

Sara J. Buhrlage, Ph.D.

Affiliations: 
2015 Harvard Medical School/Dana-Farber Cancer Institute, Boston, MA, United States 
Area:
Chemical biology
Google:
"Sara Buhrlage"
Mean distance: 8.57
 		SNBCP
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Anna K. Mapp grad student 2008 University of Michigan
 (Small molecule transcriptional activation domains.)
Nathanael Gray research scientist 2010-2015 Harvard Medical School/Dana-Farber Cancer Institute

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Munshi M, Liu X, Kofides A, et al. (2022) A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Advances
Yang J, Weisberg EL, Qi S, et al. (2022) Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia
Yang J, Weisberg EL, Liu X, et al. (2021) Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia
Yang G, Wang J, Tan L, et al. (2021) The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood
Koduri V, Duplaquet L, Lampson BL, et al. (2021) Targeting oncoproteins with a positive selection assay for protein degraders. Science Advances. 7
Donovan KA, Ferguson FM, Bushman JW, et al. (2020) Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell
Hatcher JM, Yang G, Wang L, et al. (2020) Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. Acs Medicinal Chemistry Letters. 11: 2238-2243
Weisberg E, Parent A, Yang PL, et al. (2020) Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharmaceutical Research. 37: 167
Schauer NJ, Liu X, Magin RS, et al. (2020) Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Scientific Reports. 10: 5324
Weisberg E, Meng C, Case A, et al. (2020) Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia
See more...